2.1. Description of the Study Collective
Our center included and randomized 15 patients to receive either the allogeneic ADSCs or the placebo. All 15 patients were male, and the mean age was 62 ± 8 years. Ten patients received the active substance (allogeneic ADSCs) (62 ± 8 years) and 5 patients the placebo (61 ± 9 years), administered by percutaneous 3D NOGA-guided intramyocardial injections. Thirteen patients were previous or active smokers, with a mean of 40.1 ± 21.6 pack years (ADSC: 43.2 ± 24.8 years, placebo: 36.0 ± 15.4 years, 